nâ-â3 Docosapentaenoic acid: the iceberg nâ-â3 fatty acid.
Curr Opin Clin Nutr Metab Care
; 24(2): 134-138, 2021 03 01.
Article
em En
| MEDLINE
| ID: mdl-33315722
ABSTRACT
PURPOSE OF REVIEW Docosapentaenoic acid (DPA) is a minor omega-3 fatty acid (FA) which has been frequently overlooked in lipid research. This review examines the biochemical and physiological outcomes of human trials which have used pure preparations of DPA (nâ-â3 DPA) and also recent developments in specialized proresolving lipid mediators (SPMs) derived from nâ-â3 DPA. RECENT FINDINGS:
There have been only been two human studies and eleven animal studies with pure nâ-â3 DPA. The doses of nâ-â3 DPA used in the human trials have been 1-2âg/day. nâ-â3 DPA abundance is increased in blood lipid fractions within 3-4 days of supplementation. nâ-â3 DPA has the potential for unique properties, with a greater similarity in biological functioning with docosahexaenoic acid (DHA), than eicosapentaenoic acid (EPA). Despite the typically low levels of nâ-â3 DPA in most tissue lipids relative to EPA and DHA, unique SPMs, such as resolvins, maresins and protectins of the nâ-â3 DPA type, are involved in resolution of inflammation and regulating immune function.SUMMARY:
We suggest that measurement of blood levels of nâ-â3 DPA gives no indication of its broad biological roles, but that the true functionality of this enigmatic nâ-â3 polyunsaturated fatty acid (PUFA) remains obscure until more is known about the properties of the unique DPA-derived SPMs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ácidos Graxos Ômega-3
/
Ácidos Graxos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Clin Nutr Metab Care
Assunto da revista:
CIENCIAS DA NUTRICAO
/
METABOLISMO
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Austrália